A surveillance on protease inhibitor resistance-associated mutations among iranian hiv-1 patients

Nasiri-Tajabadi, Z. and Salim, F. B. and Najafzadeh, M. J. and Kalantari, S. and Garshasbi, S. and Jamehdar, S. A. and Farsiani, H. and Mazaheri, Z. and Sankian, M. and Youssefi, M. (2018) A surveillance on protease inhibitor resistance-associated mutations among iranian hiv-1 patients. Archives of Clinical Infectious Diseases, 13 (6).

[img] Text
A surveillance on protease inhibitor resistance-associated mutations among iranian hiv-1 patients.pdf

Download (136kB)

Abstract

Background: Drug resistance is emerging as one of the greatest challenges in the development of effective treatment for HIV infection. The importance of clinical studies in this field stems from the world wide growing of treatment drug-resistant mutations. Objectives: This study was performed to determine the HIV subtype and the resistance mutations to the protease inhibitors in both untreated HIV patients and patients under treatment with protease inhibitors (PIs) in Iran. Methods: The study was conducted on two groups of participants. The first group consisted of 25 HIV patients who did not receive any antiretroviral treatment. The second group included 25 HIV patients who have being treated with a combination of protease inhibitors. After genome extraction, a nested polymerase chain reaction was performed to amplify the protease gene. Upon confirmation using electrophoresis, the amplicons or PCR products were sequenced and analyzed to determine the drug resistance mutations as well as the viral subtypes. Results: No mutations were found in the first group; however, 32 of the samples in the second group had PI related drug-resistance mutations. The major mutations were V82A and M46I, which were seen in 12 of the samples, while the minor mutation F53L was seen in 16 of the samples. The subtype analysis showed that 94 of the samples were subtype CRF35AD, and 6 were of defined as subtype A. Conclusions: The present study reports updates on the mutations related to protease resistance in Iranian HIV patients receiving treatment. Our data, as well as existing reports, support the need for the optimization of treatment to prevent emergence of resistant viruses and a search for new antiretroviral drug candidates for HIV patients. © 2018, Archives of Clinical Infectious Diseases.

Item Type: Article
Additional Information: Export Date: 16 February 2020 Correspondence Address: Youssefi, M.; Central Lab., Imam Reza University Hospital, Imam Reza Sq., Iran; email: youssefim@mums.ac.ir
Uncontrolled Keywords: Drug Resistance HIV Mutation Protease Inhibitor atazanavir darunavir Human immunodeficiency virus proteinase Human immunodeficiency virus proteinase inhibitor lopinavir lopinavir plus ritonavir nelfinavir ritonavir adolescent adult Article child clinical article controlled study cross-sectional study female gene amplification gene sequence human human cell Human immunodeficiency virus 1 infection Iranian people male nonhuman nucleotide sequence virus genome virus mutation
Subjects: WC Communicable Diseases
QV pharmacology
QZ pathology-neoplasms-Genetics
Divisions: Mashhad University of Medical Sciences
Depositing User: lib2 lib2 lib2
Date Deposited: 07 May 2020 07:12
Last Modified: 07 May 2020 07:12
URI: http://eprints.mums.ac.ir/id/eprint/17450

Actions (login required)

View Item View Item